RxDoctor Payments Data

Brenda Peart, MD

Interventional Cardiology · Tucson, AZNPI 1700882651

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.3% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 92.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for interventional cardiology clinicians in AZ, where the typical reported total is $10,657.

$182in general payments, 2019–2025

Across 8 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$168
  • AstraZeneca$14
$65,473in research payments, 2019–2025

Across 21 payments — averaging $3117.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$36K
  • Merck$21K
  • American Regent$9K

What the payments were for

  • Food & beverage$16892%
  • Education$148%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific7$168
AstraZeneca1$14

How this compares

$182 in reported general payments places this provider in the 0th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$217,632
Medicare patients
1,032
Services billed
2,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban505$575,877
Repatha SureclickEvolocumab400$435,097
XareltoRivaroxaban160$222,221
EntrestoSacubitril/Valsartan129$199,561
MultaqDronedarone Hcl105$152,080
JardianceEmpagliflozin64$80,322
OzempicSemaglutide33$44,051
Praluent PenAlirocumab31$36,461
MounjaroTirzepatide21$29,827
BrilintaTicagrelor20$23,182
CorlanorIvabradine Hcl31$13,212
NexletolBempedoic Acid13$11,123
Repatha SyringeEvolocumab12$11,086
Ezetimibe369$6,392
Flecainide Acetate141$6,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$14$23,18220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →